JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Lista de Ações・Sanofi

Sanofi

Fechado

43.37 0.18

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

43.08

Máximo

43.52

Indicadores-chave
By Trading Economics
Rendimento	2.4B 1.6B
Vendas	-961M 11B
P/E Médio do Setor	19.885 67.147
EPS	1.102
Margem de lucro	14.354
Funcionários	74,846
EBITDA	-1.1B 2.7B

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+22.26% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-11B 104B
Abertura anterior	43.19
Fecho anterior	43.37

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

51.665 / 52.38 Suporte e Resistência

Sanofi Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de abr. de 2026, 06:12 UTC

Ganhos

Sanofi Posts Higher Sales Amid Leadership Transition

12 de fev. de 2026, 12:40 UTC

Grandes Movimentos do Mercado

Sanofi Shares Fall After CEO Change

29 de jan. de 2026, 11:35 UTC

Ganhos

Sanofi Remains Committed to Vaccines After Mixed Year for Drug Pipeline -- Update

29 de abr. de 2026, 12:01 UTC

Ganhos

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

27 de abr. de 2026, 09:32 UTC

Conversa de Mercado

Ganhos

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

27 de abr. de 2026, 09:19 UTC

Conversa de Mercado

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

23 de abr. de 2026, 05:34 UTC

Ganhos

Sanofi: 2026 Expectations Are at Constant Exchange Rates

23 de abr. de 2026, 05:34 UTC

Ganhos

Sanofi Sees Business EPS Growth Slightly Faster Than Sales in 2026

23 de abr. de 2026, 05:34 UTC

Ganhos

Sanofi Sees Sales Growth by a High Single-Digit Percentage in 2026

23 de abr. de 2026, 05:34 UTC

Ganhos

Sanofi Backs 2026 View

23 de abr. de 2026, 05:33 UTC

Ganhos

Sanofi 1Q Business Net Pft EUR2.26B

23 de abr. de 2026, 05:33 UTC

Ganhos

Analysts Saw Sanofi 1Q Business Oper Pft at EUR2.85B

23 de abr. de 2026, 05:33 UTC

Ganhos

Sanofi 1Q Business Oper Pft EUR2.97B

23 de abr. de 2026, 05:32 UTC

Ganhos

Analysts Saw Sanofi 1Q Net Sales at EUR10.22B

23 de abr. de 2026, 05:32 UTC

Ganhos

Sanofi 1Q Net Sales Rose 14% on Year at Constant Exchange Rates

23 de abr. de 2026, 05:31 UTC

Ganhos

Sanofi 1Q Net Sales EUR10.51B

10 de abr. de 2026, 11:12 UTC

Conversa de Mercado

Sanofi Investors Might Have to Wait for Update on Strategy -- Market Talk

10 de abr. de 2026, 10:54 UTC

Conversa de Mercado

Sanofi Could Get Boost From Dupixent U.S. Price -- Market Talk

30 de mar. de 2026, 10:40 UTC

Conversa de Mercado

Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk

27 de mar. de 2026, 10:40 UTC

Conversa de Mercado

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

11 de mar. de 2026, 11:02 UTC

Conversa de Mercado

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

24 de fev. de 2026, 14:00 UTC

Aquisições, Fusões, Aquisições de Empresas

This Small-Cap Biotech Stock Is Soaring 35% on Excitement Over Its Prostate Cancer Drug -- Barrons.com

13 de fev. de 2026, 08:21 UTC

Conversa de Mercado

Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk

12 de fev. de 2026, 15:20 UTC

Ganhos

Sanofi Shares Fall After CEO Change -- Update

10 de fev. de 2026, 14:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Sanofi Set Out $2.2 Bln Cash Deal for Dynavax Late Last Year

10 de fev. de 2026, 14:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Sanofi: Acquisition Includes Dynavax's Hepatitis B Vaccine, Shingles Vaccine Candidate

10 de fev. de 2026, 14:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Sanofi Completes Acquisition of Dynavax

10 de fev. de 2026, 14:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Press Release: Sanofi Completes The Acquisition Of Dynavax >SAN.FR

6 de fev. de 2026, 12:35 UTC

Ganhos

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

29 de jan. de 2026, 13:00 UTC

Conversa de Mercado

Ganhos

Sanofi Results Encourage, But Pipeline Strategy Should Take Priority -- Market Talk

Comparação entre Pares

Variação de preço

Sanofi Previsão

Preço-alvo

By TipRanks

22.26% parte superior

Previsão para 12 meses

Média 53 USD 22.26%

Máximo 57 USD

Mínimo 50 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Sanofi - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

3 ratings

Comprar

Manter

Vender

Com base em 3 analistas que deram avaliações de ações para Sanofi - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

51.665 / 52.38Suporte e Resistência

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.